Vantia Therapeutics
SOUTHAMPTON, England, July 6, 2011 -
Vantia Therapeutics, an emerging pharmaceutical company
developing novel, small molecule drugs targeting large areas of
unmet medical need, today announces it has raised 4 million ($6.5
million) in a series B round.
SOUTHAMPTON, England, February 2 - Vantia Therapeutics, an emerging pharmaceutical company
developing novel, small molecule drugs targeting large, underserved medical
markets, today announces it has begun its planned Phase IIb trial of its lead
development compound VA106483 for nocturia.
SOUTHAMPTON, England - Vantia Therapeutics today announces that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered Phase II proof-of-concept trials.
SOUTHAMPTON, England - Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia.
SOUTHAMPTON, England - Vantia Therapeutics, a company developing novel small molecule drugs targeting large underserved medical markets, today announces the appointment of Rachel Morten as Head of Regulatory Affairs.
